RCS - Immupharma PLC - IMMUPHARMA AT BIO-EQUITY 2024 12-14 May

ImmuPharmaAnnouncement

24/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240424:nRSX7666La&default-theme=true

RNS Number : 7666L  Immupharma PLC  24 April 2024

 

RNS REACH | 24 April 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

IMMUPHARMA AT BIO-EQUITY 2024

12-14 May 2024, SAN SEBASTIAN

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be
attending BIO-Equity. The event will be held from 12-14 May 2024, in San
Sebastian, Spain.

BIO-Equity is an annual premier partnering event, designed to provide
biotechnology companies with the opportunity to present to and connect with
investors together with the global biopharma community. This event provides an
important continuum for ImmuPharma to facilitate ongoing discussions regarding
potential global partnering deals across its pipeline portfolio.

Commenting on the event, Tim McCarthy, CEO of ImmuPharma said: "Further to our
clinical progress with P140 in SLE and CIDP, attending BIO-Equity 2024 offers
the opportunity to continue discussions on our unique portfolio with specific
bioPharma companies and investment specialists, particularly in relation to
SLE, CIDP and potentially other autoimmune diseases within our P140 technology
platform. Our focus remains on track to establish global partnering
opportunities across all our programs."

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 is a first-in class autophagy
immunomodulator for the treatment of Lupus and CIDP and preclinical analysis
suggests P140 may have therapeutic benefit in many other autoimmune diseases
that are caused by the same dysfunction in the immune system.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 16
million individuals worldwide. The current standard of care still consists of
steroid and anti-malarial therapies which many have side-effects and poor
response in many patients. Recently more targeted monoclonal therapies are
GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There
still exists a high unmet medical need for a drug that has a strong efficacy
and safety profile.

 

About CIDP (Chronic Idiopathic Demyelinating Polyneuropathy)

 

CIDP is a rare acquired autoimmune disorder of peripheral nerves which is
thought to affect some 90 thousand individuals across US/Europe.  It is a
rare neurological disorder characterized by progressive weakness and impaired
sensory function in the legs and arms. CIDP related disability may be
substantial. In addition to the physical burdens imposed by the disease, those
affected by CIDP also frequently experience economic and emotional hardship
and are often burdened not only by the disease but also by the immunotherapies
used to treat the disease. Other than intravenous (IVIG) and subcutaneous
immunoglobulin (SCIG), corticosteroids and plasma exchange are the only other
treatment options. There is still a huge unmet need for more efficacious drugs
that are safer, and which affect underlying disease progression.

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFITSFIVFIS